| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/14/2002 | DE10043124A1 Verfahren zur Diagnostik von neuronalen Erkrankungen sowie zur Behandlung der defizienten primären Hämostase Method for the diagnosis of neural disorders and for the treatment of primary hemostasis deficiency |
| 03/14/2002 | DE10023486C1 Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel Ortho-substituted anthranilic acid amides and their use as medicaments |
| 03/14/2002 | CA2730627A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | CA2422204A1 Human antibodies against pseudomonas aeruginosa lps derived from transgenic mice |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421842A1 Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders |
| 03/14/2002 | CA2421718A1 Protein tyrosine phosphatase inhibitor |
| 03/14/2002 | CA2421581A1 Benzene tricarboxylic acid amides as insulin receptor activators |
| 03/14/2002 | CA2421380A1 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | CA2421374A1 Methods and compositions for diseases associated with amyloidosis |
| 03/14/2002 | CA2421271A1 Human and mouse targeting peptides identified by phage display |
| 03/14/2002 | CA2421213A1 The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 03/14/2002 | CA2421200A1 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | CA2421195A1 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | CA2421191A1 Methods and compositions for in vitro targeting |
| 03/14/2002 | CA2421172A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 03/14/2002 | CA2421018A1 Dihydroxy open-acid salt of simvastatin |
| 03/14/2002 | CA2420703A1 Quinoline and quinazoline derivatives as ligands for the neuropeptide y receptor |
| 03/14/2002 | CA2417594A1 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors |
| 03/14/2002 | CA2417177A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/14/2002 | CA2389739A1 Mimetic peptides for epitope of apolipoprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same |
| 03/13/2002 | EP1186672A2 Polymorphisms in the human organic anion transporter C (OATP-C) gene |
| 03/13/2002 | EP1186293A2 Intermittent administration of a growth hormone secretagogue |
| 03/13/2002 | EP1185862A2 Method and compositions relating to insulin resistance disorders |
| 03/13/2002 | EP1185700A1 49 human secreted proteins |
| 03/13/2002 | EP1185696A1 Antisense oligonucleotide modulation of human protein kinase c-delta expression |
| 03/13/2002 | EP1185694A1 49 human secreted proteins |
| 03/13/2002 | EP1185643A1 Adipocyte complement related protein homolog zacrp5 |
| 03/13/2002 | EP1185558A1 Peptide having preptin functionality |
| 03/13/2002 | EP1185554A1 Peptide having for fibrinogen fragment e activity, analogs, antibodies and uses thereof |
| 03/13/2002 | EP1185549A2 Dna encoding a human subunit of the 5-ht3 serotonin receptor |
| 03/13/2002 | EP1185543A1 50 human secreted proteins |
| 03/13/2002 | EP1185542A2 Purine derivatives |
| 03/13/2002 | EP1185539A1 Organosilyl compounds having nuclear hormone receptor modulating activity |
| 03/13/2002 | EP1185316A1 Devices and compounds for treating arterial restenosis |
| 03/13/2002 | EP1185304A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells |
| 03/13/2002 | EP1185302A2 Specifically targeted catalytic antagonists and uses thereof |
| 03/13/2002 | EP1185296A2 Prevention and treatment of amyloidogenic disease |
| 03/13/2002 | EP1185277A1 Methods for modulating fxr receptor activity |
| 03/13/2002 | EP1185275A1 Aminopyrimidines as sorbitol dehydrogenase inhibitors |
| 03/13/2002 | EP1185274A1 Drug combinations comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4 |
| 03/13/2002 | EP1185272A2 Novel use of 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts |
| 03/13/2002 | EP1185263A2 Receptor agonists and antagonists |
| 03/13/2002 | EP1185252A1 Novel formulations comprising lipid-regulating agents |
| 03/13/2002 | EP1185247A1 Anti-inflammatory bioactive glass particulates |
| 03/13/2002 | EP1185175A1 Method of increasing the content of flavonoids and phenolic substances in plants |
| 03/13/2002 | EP1023030A4 Method and bottle for infant feeding |
| 03/13/2002 | EP0802910B1 Estrogen agonists/antagonists |
| 03/13/2002 | CN1340058A Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 03/13/2002 | CN1340052A Process for the production of tert-butyl (E)-(6[2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin 5-yl] (4R,6S)-2,2-dimethyl [1,3] dioxan-4-yl) acetate |
| 03/13/2002 | CN1340049A 4-heterocyclylsulfonamide)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl-or-pyridylpyrimidines as endothelin receptor antagonists |
| 03/13/2002 | CN1340045A 5-HTIF agonists |
| 03/13/2002 | CN1340044A Nervinolin derivatives |
| 03/13/2002 | CN1339973A Gene therapy for diabetic ischemic disease |
| 03/13/2002 | CN1339971A Application polyacrylamide gel for forming a capsule in the tissue of a mammal organism, method for cultivating cells and method for therapy of tumor and diabetes mellitus |
| 03/13/2002 | CN1339967A Composition for treatinb obesity and aesthetic treating method |
| 03/13/2002 | CN1339441A General glycoside extracted from pomegranate leaf and astragalus root and its producing method |
| 03/13/2002 | CN1339314A Processing method of medicinal powder for diabetes |
| 03/13/2002 | CN1339303A Functional food for reducing blood fat and promoting blood circulation |
| 03/13/2002 | CN1339301A New lactic acid fungus preparation having biological purifying activity |
| 03/13/2002 | CN1080718C Vitamin D amine and amine derivatives |
| 03/13/2002 | CN1080566C Mixtures derived from eugenia jambolana lamarck, preparation and use of said mixtures and some of their constituents as medicines |
| 03/12/2002 | US6355811 Polyoxypropylenepolyethylene vitamin E and preparation thereof |
| 03/12/2002 | US6355680 Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
| 03/12/2002 | US6355670 Skin disorders |
| 03/12/2002 | US6355666 Protected forms of pharmacologically active agents and uses therefor |
| 03/12/2002 | US6355645 4-(3'-bromobenzoyl)-6,7-dimethoxyquinazoline; for lowering blood cholesterol, including reducing total cholesterol and ldl-cholesterol levels |
| 03/12/2002 | US6355640 Pyrazolopyridine adenosine antagonists |
| 03/12/2002 | US6355618 Enzyme inhibitors |
| 03/12/2002 | US6355613 Cyclized oligopeptides with bridging groups of amide, thioether, thioester or disulfide |
| 03/12/2002 | US6355609 Methods for stabilizing liquid nutritional products and products so stabilized |
| 03/12/2002 | US6355479 Insect polypeptide for use in the treatment of autoimmune diseases, allergies and cancer |
| 03/12/2002 | US6355446 DocosahexAenoic acid as retinoid X-receptor ligand and uses thereof |
| 03/12/2002 | US6355279 Administering an extraction solution, not containing the resulting extraction residue, of at least one member selected from gajutsu (zedoariae rhizoma) and kyouou (curcumae rhizoma) for lowering blood triglyceride levels |
| 03/12/2002 | US6355274 Encapsulated long chain alcohols |
| 03/12/2002 | US6355265 Over-coated chewing gum formulations |
| 03/12/2002 | US6355258 Method for formulating spill resistant pharmaceutical compositions in semi-solid form |
| 03/12/2002 | US6355241 In vivo production and delivery of erythropoietin |
| 03/12/2002 | CA2313783C Pharmaceutical compositions of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid or a salt thereof |
| 03/12/2002 | CA2064077C T cell receptor peptides as therapeutics for autoimmune and malignant disease |
| 03/07/2002 | WO2002018623A2 Methods and reagents for protease inhibition |
| 03/07/2002 | WO2002018553A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | WO2002018445A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | WO2002018437A2 Cyclic peptides having melanocortin-4 receptor agonist activity |
| 03/07/2002 | WO2002018436A1 Product and method for control of obesity |
| 03/07/2002 | WO2002018432A2 Protein extracted from the intestines of vertebrates, which absorbs cholesterol, and the use of this protein for identifying inhibitors of intestinal cholesterol transport |
| 03/07/2002 | WO2002018395A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | WO2002018386A1 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES |
| 03/07/2002 | WO2002018385A1 1-[ALKYL], 1-[(HETEROARYL)ALKYL] AND 1-[(ARYL)ALKYL]-7-PYRIDINYL-IMIDAZO[1,2-a]PYRIMIDIN-5(1H)-ONE DERIVATIVES |
| 03/07/2002 | WO2002018382A1 Pyrazolopyridine compound and pharmaceutical use thereof |
| 03/07/2002 | WO2002018379A2 7-oxo pyridopyrimidines |
| 03/07/2002 | WO2002018377A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/07/2002 | WO2002018363A2 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors |
| 03/07/2002 | WO2002018361A2 Compounds having activity as inhibitors of cytochrome p450rai |
| 03/07/2002 | WO2002018355A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| 03/07/2002 | WO2002018350A1 Grk inhibitor |
| 03/07/2002 | WO2002018346A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | WO2002018340A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS |
| 03/07/2002 | WO2002018327A2 Guanidinobenzamides as mc4-r agonists |
| 03/07/2002 | WO2002018323A2 Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors |